Skip to content
Screener

D&A at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$172.3M+11.6%
Biogen logo
BiogenBIIB
$236.1M+21.5%

Segments

By segment

See full
Reportable Segment$33K-28.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$8.9B+770%
Enterprise value$8.43B+873%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

FAQ

What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.